Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. MD Anderson Cancer Center, University of Texas, Houston, TX, United States

Survival: 17.8 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Houston, TX
Hospital: MD Anderson Cancer Center, University of Texas
Journal: Link
Date: 3/2010

This phase 2 study involved 39 women with platinum refractory or resistant ovarian cancer. The median age was 54.5 years, with a range of 34.8-75.4.

Patients received a combination of two chemotherapeutic agents, canfosfamide (also known as TELCYTA or TLK286) and pegylated liposomal doxorubicin.

The highest toxicity level observed in this study was Grade 4, mostly consisting of neutropenia. Other adverse events observed at a level less that 4 included nausea, fatigue, hair loss, and stomatitis (inflammation of the mouth).

The median overall survival reported in this study was 17.8 months. The reported median progression-free survival was 6 months.

Several of the authors are employed by Telik, Inc, the makers of canfosfamide.

Correspondence: Dr. Gail L. Brown

E-mail to a Friend Email Physician More Information